NASDAQ · MEDP
Medpace Holdings, Inc.
Healthcare · Medical - Diagnostics & Research
$669.20▲ 2.33% ($15.23)at close
As of 4:00 PM ET
Market cap
$18.72B
P/E
36.67
EPS (TTM)
$18.25
Next earnings
Valuation
Revenue & margin DCF
Verdict: fairly priced. Price above Base.
The price needs 17.9% revenue growth a year for 10 years. Our scenarios assume 7.7–13.4%.
That's below its past 4-year pace of 22.0%.
Value per share
Base case
$408.45
Price used $669.20 is 1.6× this
USD · TTM ending Sep 30, 2026 · Price Oct 23, 8:00 PM UTC
Revenue each value needs
Revenue today $2.8B. The price needs $14.8B by 2036. Base case: $7.9B. At its recent pace: $20.7B. Bear to Bull: $6B to $10B.
Revenue today $2.8B. The price needs $14.8B by 2036. Base case: $7.9B. At its recent pace: $20.7B. Bear to Bull: $6B to $10B.
Revenue in 2036
today $2.8B
+$6.9Bmore than the Base case · 1.9×
Value per share · Base case
$408.45
Price $669.20
1.6× this
- 10-yr revenue CAGR
- 10.7%
- Ending operating margin
- 14.1%
- Discount rate
- 10.0%
USD · TTM ending Sep 30, 2026 · Price Oct 23, 8:00 PM UTC
What each scenario assumes. Click a column to start from it.
Price vs Fundamentals
Why The Stock Is Moving
What changed
The stock rose 12.17% over the last year. Revenue grew 20.35% over the trailing twelve months. Operating margin moved from 21.5% to 21.39%. Free cash flow declined 5.11% over the trailing twelve months.
What the market seems to be pricing
The stock is trading toward the richer end of its historical P/FCF range (98th percentile) while business metrics are improving. More of the upside is already embedded in the multiple now.
What would invalidate this read
Operating margin is at 21.39% — continued expansion would be needed to justify the premium. Revenue growth of 20.35% is encouraging, but any deceleration puts the stretched multiple at risk. This read changes if revenue, margins, and cash flow continue to improve faster than expected — in that case the richer multiple could still prove conservative.
Return analysis
Company profile
Medpace Holdings, Inc., founded in Cincinnati, Ohio, in 1992, functions as a contract research organization (CRO) delivering clinical development and research services.
Market multiples
Stock splits
No stock splits recorded for this ticker.
Profitability & growth
Analyst consensus
4
Buy
15
Hold
0
Sell
Analyst ratings tend to be lagging indicators. Use as one signal among many.
Earnings
Actuals vs estimates by quarter, or any quarter against the same one a year earlier.
Next report
Feb 8, 2027
Q4 FY26 · EPS est $4.82 · Revenue est $718.4M
Same quarter, year over year
FY26 YTD +25.8%Each cell vs the same quarter a year earlier (the cell below) · Q1–Q3 combined $13.37 vs $10.63 · all 3 quarters up
Q1
Q2
Q3
Q4
FY total
FY26
—
FY25
FY24
FY23
—
—
—
—
Fiscal year totals
- FY25
- $15.30
- +21.1%
- FY24
- $12.63
- —
Q3 FY26
Reported Oct 21, 2026 · Latest
HoverTap a cell to inspect
Actual
$4.84
Estimate
$4.44
Year over year
+25.4%
Vs prior quarter
+13.9%
Institutional Sentiment
Medpace Holdings, Inc. · MEDP
From Form 13F filings (managers with $100M+). Filings land up to 45 days after quarter end — read this as positioning context, not live fund flow.